AL
ALT.US Altimmune Inc
- Market cap
- USD 320M
- P/E
- -
- P/B
- 0.72x
- ROE
- -23.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ALT.US undervalued?
Graham numberThe Graham number of Altimmune Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Altimmune Inc fundamental analysis
No fundamental analysis for Altimmune Inc yet.
Altimmune Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Altimmune Inc
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Full company profileAltimmune Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Altimmune Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.23M | 41.5K | 10.3M | 5.80M | 8.19M | 4.41M | -68.0K | 426K | 20.0K | 41.0K | - |
| Gross Profit | -1.99M | -18.4M | -8.13M | 5.80M | -25.3M | 4.41M | -68.0K | 426K | 20.0K | 41.0K | -82.6M |
| Operating Income | -11.3M | -52.0M | -42.8M | -21.5M | -54.8M | -96.9M | -87.7M | -95.9M | -103M | -94.5M | -115M |
| EBITDA | -10.9M | -51.8M | -44.7M | -20.2M | -38.1M | -96.5M | -84.4M | -87.9M | -94.8M | -87.0M | -98.2M |
| Net Income | 194M | -46.4M | -39.2M | -20.5M | -49.0M | -97.1M | -84.7M | -88.4M | -95.1M | -88.1M | -103M |
| EPS | 841 | -109 | -14 | -1.56 | -1.91 | -2.35 | -1.81 | -1.66 | -1.34 | -1.00 | -0.50 |
| Balance Sheet | |||||||||||
| Total Assets | 225M | 63.0M | 54.8M | 54.1M | 245M | 219M | 207M | 211M | 139M | 280M | 496M |
| Total Liabilities | 205M | 14.4M | 6.44M | 8.54M | 19.2M | 19.7M | 21.6M | 16.5M | 15.8M | 55.0M | 52.1M |
| Shareholders' Equity | 19.5M | 48.7M | 48.3M | 45.5M | 226M | 199M | 185M | 194M | 124M | 225M | 444M |
| Cash & Short-term Investments | 221M | 8.77M | 33.7M | 37.2M | 216M | 190M | 185M | 198M | 132M | 273M | 265M |
| Total Debt | 1.99M | 4.62M | 1.92M | 2.12M | 2.19M | 1.87M | 1.12M | 671K | 1.68M | 35.7M | 35.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 202M | -20.2M | -9.39M | -9.60M | -34.4M | -78.2M | -62.6M | -75.8M | -79.8M | -67.5M | -111M |
| Capital Expenditure | 30.7K | 166K | 1.02M | 29.0K | 342K | 12.3M | 126K | 47.0K | 0.00 | 11.0K | 156K |
| Free Cash Flow | 201M | -20.4M | -10.4M | -9.63M | -34.8M | -90.6M | -62.7M | -75.9M | -79.8M | -67.5M | -111M |
| Ratios | |||||||||||
| ROE | 996.2% | -95.4% | -81.1% | -45.1% | -21.7% | -48.8% | -45.7% | -45.6% | -77.0% | -39.2% | -23.1% |
| ROA | 86.3% | -73.7% | -71.5% | -38.0% | -20.0% | -44.4% | -40.9% | -42.0% | -68.2% | -31.5% | -20.7% |
| Net Profit Margin | 3,706.4% | -111,860.3% | -379.2% | -353.7% | -599.2% | -2,201.6% | - | -20,762.2% | -475,295.0% | -214,861.0% | - |
| Debt to Equity | 0.10x | 0.09x | 0.04x | 0.05x | 0.01x | 0.01x | 0.01x | 0.00x | 0.01x | 0.16x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Altimmune Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jan 20, 2017
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 135M | 5.28 | - |
| 2019 | USD 3.79B | 289 | - |
| 2018 | USD 22.9K | 0.01 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:30 on Sep 14, 2018.
Who owns Altimmune Inc
- Insiders 0.72%
- Institutions 76.45%
- Public & others 22.83%
- Shares outstanding 195M
- Free float 164M
Top funds holding ALT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 5.75M | 2.96% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 4.84M | 2.49% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 4.78M | 2.46% | +2.69% | Oct 2026 |
| Vanguard Strategic Equity Inv | 2.95M | 1.52% | +10.49% | Sep 2026 |
| Fidelity Small Cap Index | 2.19M | 1.12% | +0.60% | Aug 2026 |
| iShares Russell 2000 Value ETF | 1.78M | 0.92% | 0.00% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 1.51M | 0.77% | +0.27% | Oct 2026 |
| iShares Biotechnology ETF | 1.46M | 0.75% | -0.19% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 1.36M | 0.70% | +0.21% | Sep 2026 |
| Vanguard Explorer Inv | 1.21M | 0.62% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 1.12M | 0.57% | -2.37% | Sep 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 974K | 0.50% | +12.35% | Sep 2026 |
| Fidelity Extended Market Index | 706K | 0.36% | -11.40% | Sep 2026 |
| iShares Micro-Cap ETF | 581K | 0.30% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 478K | 0.25% | +0.11% | Sep 2026 |
| Schwab Small Cap Index | 467K | 0.24% | -3.44% | Sep 2026 |
| Vanguard Market Neutral I | 401K | 0.21% | +16.60% | Jun 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 382K | 0.20% | -6.51% | Sep 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 360K | 0.19% | +0.03% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 358K | 0.18% | -3.68% | Sep 2026 |
Top institutions holding ALT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 20.4M | 10.48% | +59.32% | Jun 2026 |
| Deep Track Capital, LP | 19.3M | 9.90% | 0.00% | Jun 2026 |
| State Street Corp | 12.1M | 6.22% | +69.32% | Jun 2026 |
| TCG Crossover Management, LLC | 10.0M | 5.14% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 8.18M | 4.20% | +44.53% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 7.33M | 3.77% | +36.20% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 6.84M | 3.52% | +70.26% | Jun 2026 |
| Viking Global Investors LP | 6.70M | 3.44% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 6.50M | 3.34% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 5.01M | 2.58% | +61.29% | Jun 2026 |
| Woodline Partners LP | 3.40M | 1.75% | 0.00% | Jun 2026 |
| Millennium Management LLC | 3.31M | 1.70% | +1.56% | Jun 2026 |
| Nantahala Capital Management, LLC | 3.00M | 1.54% | 0.00% | Jun 2026 |
| Trails Edge Capital Partners, LP | 2.66M | 1.37% | 0.00% | Jun 2026 |
| Nuveen, LLC | 2.41M | 1.24% | +3.03% | Jun 2026 |
| Two Sigma Investments LLC | 2.38M | 1.22% | -3.94% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.21M | 1.14% | +63.95% | Jun 2026 |
| Great Point Partners LLC | 1.74M | 0.90% | 0.00% | Jun 2026 |
| Northern Trust Corp | 1.60M | 0.82% | +60.45% | Jun 2026 |
| Weiss Asset Management LP | 1.53M | 0.79% | 0.00% | Jun 2026 |
Altimmune Inc company profile
- Company name
- Altimmune Inc
- Ticker
- ALT.US
- Exchange
- USA Stocks
- Listed since
- Oct 6, 2005
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 57
- Fiscal year end
- December
- Address
- 910 Clopper Road, Gaithersburg, MD, United States, 20878
- Phone
- 240 654 1450
- Website
- altimmune.com
About Altimmune Inc
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Altimmune Inc management
10- Mr. Jerome Benedict DursoChairman, CEO & President · born 1968
- Dr. M. Scot Roberts Ph.D.Chief Scientific Officer · born 1959
- Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D.Chief Medical Officer · born 1963
- Mr. Gregory L. Weaver CPA, M.B.A.Chief Financial Officer · born 1956
- Mr. Richard MenziusoVP, Global Controller & Principal Accounting Officer · born 1975
- Mr. Bertrand Georges Ph.D.Chief Technology Officer
- Mr. Luis Sanay C.F.A.Vice President of Investor Relations
- Mr. Tony Blandin B.S.Vice President of Quality & Compliance Management
- Ms. Robin E. Abrams J.D.Chief Legal Officer & Corporate Secretary · born 1964
- Mr. Raymond M. Jordt M.B.A., M.S.Chief Business Officer · born 1973